Eli Lilly Odipositas Pill beats Novo Nordisk Drug in Diabetes Study
A sign with the company logo is located on March 17, 2024 outside the headquarters Eli Lilly in Indianapolis, Indiana.
Scott Olson | Getty pictures
Eli Lilly On Wednesday, his experimental pill surpassed Novo NordiskYour own oral medicinal products in the first head-to-head study in which the two medicines are compared in patients with type 2 diabetes.
As an Eli Lillys Pille, the study in the late stage is closer to becoming another needle-free alternative on the blockbuster market for GLP-1 without dietary restrictions. But it may be too early to establish a clear winner in the pill room, since there is no data in which the drug by Eli Lilly is compared with a higher dose of Novo Nordisks Pill in patients with obesity.
Eli Lilly said that his pill, Oforlipron, was superior to the main goal of the experiment to lower the blood sugar level after 52 weeks compared to the oral semaglutide of Novo Nordisk. The highest dose of Orforlipron contributed to reducing hemoglobin A1C – a measure of blood sugar levels – by 2.2% compared to 1.4% with the pill from Novo Nordisk.
The highest dose of Eli Lillys Medicines also helped patients to lose an average of 9.2% of their weight or £ 19.7, compared to 5.3% weight loss or £ 11 with Novo Nordisks Pill. OFORGRIPRO’s weight loss was 8.2% in the analysis of all patients regardless of the discontinuations, while oral Semaglutid was 5.3%.
The results indicate that a dose of Eli Lilly of up to 36 milligrams in the treatment of diabetes patients can be more effective than one up to 14-mill-dose of oral semaglutid, which is already approved under the name Rybelus for type 2 diabetes.
“For the majority of patients, this could be the main medicine they need to control their type -2 diabetes and their obesity,” said Dan Skovronsky, Chief Scientific Officer by Eli Lilly.
Dr. Michael Weintraub, an endocrinologist at the Nyu Langone Diabetes & Endocrine Associates, said that the management of Orforlipron’s blood sugar mirror is “compared to other drugs of the type -2 -diabetes not only in comparison to other oral diabetes medication, but all type -2 diabetes medication, including injections”.
On Wednesday, the company expects the approval of Orforlipron to apply for the treatment of type -2 diabetes in 2026. Eli Lilly hopes to “start this time” this time worldwide next year, CEO David Ricks told CNBC in early August.
Eli Lilly and Novo Nordiskraffern by a larger proportion of the booming market for GLP-1S, which, according to some analysts, could have a value of around $ 100 billion in the 2030s. The room strives to enable more convenient options that the supply magnifiers and access to the hurdles created by the expensive weekly injections that currently dominate.
According to some analyst estimates, oral GLP-1 could grow from this sum at a value of $ 50 billion.
Limits of the study
However, it is less clear how Eli Lilly’s pill is compared with higher doses of oral semaglutid, especially in patients who are overweight or have obesity without diabetes. Novo Nordisk expects the US supervisory authorities to approve a higher 25 milligram dose of his pill for the treatment of obesity until the end of the year, and in a phase three study also examined a 50-milligram dose of the drug.
Wine robbery said that the comparison of the 36-milligram dose Eli Lillys Pille with oral Semaglutid can be approved in a lower dose than that in the future. “He added that patients with diabetes in a study on type -2 -diabetes patients in a study on type -2 -diabetes patients in a study on type -2 -diabetes patients typically lose less weight than patients without the disease.
Since the attempt showed that Eli Lilly’s pill better reduced blood sugar and weight compared to specific lower doses of the oral semaglutide.
Almandoz said it was “a little too early to say that you are a kind of leader in the class” of drugs. However, he said that head-to-head data are helpful because doctors determine which pill fits better for certain diabetes patients.
Detailed results in the experiment will be presented at a medical meeting and published in a journal examined by experts.
Skovronsky noticed that the company cannot carry out any studies on competitors who have not yet been approved. But he said that he was confident that Eli Lilly’s pill can beat Head-Approx.
More CNBC health insurance
Skovronsky compared the effectiveness of Orforlipron with the injectable GLP-1 “New Generation”. He seems to refer to Eli Lilly’s blockbuster -Diabetes -injections -Mo -Mounjaro and Nordo Nordisks competing shot -Ozempic.
In the meantime, Skovronsky, Orales Semaglutide “is really at a lower level, which is more similar to the GLP-1 of the first generation” like Victoza and Trulicity, older diabetes injections by Novo Nordisk or Eli Lilly.
Rybelsus has been on the market for years, which means that Eli Lilly’s pill will be a later rival in the diabetes room. However, both companies run to develop oral GLP-1 for obesity.
In contrast to Nordo Nordisks oralem Semaglutid, Eli Lillys Pille is not a peptide medication. It is a small molecule medication that is more easily absorbed by the body and does not require any restrictions on nutrition.
Test details
Eli Lilly’s Acho-3 study followed almost 1,700 adults, whose type 2 diabetes was not managed well despite taking an older diabetes medication called Metformin.
The data on the security of Orforlipron and how well the patients tolerated the drug agreed with previous studies. The most common side effects were gastrointestinal and light to moderate severity.
Eli Lilly said that 9.7% of the patients with the highest dose of his pill broke out treatment due to side effects in the study. This corresponds to 4.9% of the participants with the highest dose of Nordo Nordisks drug.
However, Eli Lilly noted that the study was not designed to compare the security and tolerability of the two medication.
Almandoz said that the security and tolerance of oreforglipron “nothing outside the empire of what you would expect” are of GLP-1S.
“I don’t think we see any signals there with Orforglipron in relation to Semaglutid,” he said.
Skovronsky said the company was “satisfied” with the tolerance and added that it was consistently carried out with GLP-1 injections.
In the meantime, Weintraub said to see a demolition rate based on side effects that are “almost twice the same” that will certainly give me a break “. He said that Eli Lilly’s pill had shown a similar rate in previous studies in the late stage, so that his gastrointestinal side effects are “probably something that we have to consider accordingly.”
